Resumen

ALVIS-ESTRADA, Luis et al. Pharmaceutical Expenditure for Diabetes Mellitus in a Region of Spain as Clinical Risk Group, 2012. Rev. Gerenc. Polit. Salud [online]. 2016, vol.15, n.30, pp.68-78. ISSN 1657-7027.  https://doi.org/10.11144/Javeriana.rgyps15-30.gfdm.

Estimations of multimorbidity associated with Type 2 Diabetes Mellitus and its relationship to pharmaceutical expenditure. Cross-sectional study during 2012. 350,015 diabetic individuals, identified through clinical codes using the International Statistical Classification of Diseases and Related Health Problem and the 3M Clinical Risk Groups software. The raw prevalence of diabetes was 6.7%. All patients were stratified into four morbidity groups. The first group corresponds to the initial state; the second group includes the core multimorbidity patients in the intermediate and advanced stages; the third group includes patients with diabetes and malignancies; the last group patients with catastrophic statuses, manly chronic renal patients. The raw prevalence of diabetes was 6.7%. The average total cost was ¬ 1257.1. Diabetes is characterized by a strong presence of other chronic conditions have a great impact on pharmaceutical spending.

Palabras clave : type 2 diabetes mellitus; drug costs; risk adjustment; hypoglycemic agents; chronic diseases; comorbidity.

        · resumen en Español | Portugués     · texto en Español     · Español ( pdf )